Navigation Links
OU research team achieves $4.5 million Defense grant
Date:5/23/2014

A University of Oklahoma research team has been awarded a five-year, $4.5 million grant from the Defense Threat Reduction Agency to address the growing problem of three specific antibiotic resistant pathogens causing devastating infections in hospitals and in persons with cystic fibrosis. The OU research team achieved the only grant of its kind to perform research that potentially will lead to the design of effective antibiotic drugs.

Helen Zgurskaya, principal investigator and professor of chemistry and biochemistry in the OU College of Arts and Sciences, will direct the investigation of these three pathogens known to resist most clinically relevant antibiotics. Co-investigators on the project include Valentin Rybenkov, professor of chemistry and biochemistry in the OU College of Arts and Sciences; and James Aggen, professor of medicinal chemistry at Northeastern University.

"Our team will focus on the structural components that make the pathogenic cells resistant to antibiotics. In the process, we also will look at physico-chemical properties that allow antibiotics to penetrate the cell membrane and determine how to make these antibiotics effective against resistant bacteria. A comparison of antibiotics with different physico-chemical properties will help us understand the mechanisms and develop a realistic predictive model that will facilitate development of antibiotics capable of penetrating the cell wall of these bacteria," says Zgurskaya.

Initially, the team will develop protocols for comparing different properties of compounds. Currently, there is no single technique to measure how various antibiotics get into the cell. Aggen will assemble a library of compounds with different properties for measurement. Rybenkov will select the best method for analyzing how compounds penetrate the cells. The team plans to use fluorescence, mass-spectroscopy and a single cell molecule methodology.

As an end goal, the team will establish a "set of rules" for how antibiotics get into the cell. This approach will not only aid in the development of new and more effective antibiotics but will suggest new approaches in the fight against human pathogens. If interested in learning more about this research, please contact Helen Zgurskaya at elenaz@ou.edu.


'/>"/>

Contact: Jana Smith
jana.smith@ou.edu
405-325-1322
University of Oklahoma
Source:Eurekalert

Related biology news :

1. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
2. Research reveals first evidence of hunting by prehistoric Ohioans
3. Diabetes Research Institute develops oxygen-generating biomaterial
4. APS issues new policy requiring identification of sex or gender in reporting scientific research
5. UC Santa Barbara researchers discover genetic link between visual pathways of hydras and humans
6. Study jointly led by UCSB researcher supports theory of extraterrestrial impact
7. U of Alberta researcher steps closer to understand autoimmune diseases
8. Research on flavanols and procyanidins provides new insights into how these phytonutrients may positively impact human health
9. A project to research biological and chemical aspects of microalgae to fuel approach
10. Scripps Research discoveries lead to newly approved drug for infant respiratory distress syndrome
11. Researchers attempt to solve problems of antibiotic resistance and bee deaths in one
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2017)... , Feb. 7, 2017   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... , its innovative, highly flexible and award winning ... customers. iMedNet is a proven Software-as-a-Service ... Electronic Data Capture (EDC), but also delivers an entire ...
(Date:2/6/2017)... , Feb. 6, 2017 According to ... are driving border authorities to continue to embrace ... there are 2143 Automated Border Control (ABC) eGates ... deployed at more than 163 ports of entry ... to 2016 achieving a combined CAGR of 37%. ...
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
Breaking Biology News(10 mins):
(Date:2/23/2017)...  Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing ... that Linda Marbán, Ph.D, president and chief executive officer, is ... Cowen and Company 37th Annual Health Care Conference ... Boston, MA 29th Annual ROTH ... pm ET) Dana Point, CA ...
(Date:2/23/2017)... DIEGO and SAN FRANCISCO ... a privately-held regenerative medicine company, and Beyond Type 1, ... with type 1 diabetes, today announced a grant from ... a functional cure for type 1 and other insulin-requiring ... ViaCyte has been developing innovative stem cell-derived cell replacement ...
(Date:2/22/2017)...  Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company ... products for companion animals, will host a live conference call ... discuss financial results from the fourth quarter and full year ... investors may access the audio webcast or use ... ...
(Date:2/22/2017)... ... February 22, 2017 , ... Park Systems , a leader in Atomic ... all SPIE attendees and Park customers on Feb. 27, 2017 from 12-2pm ... Jose Convention Center. The luncheon will feature a talk on Automated AFM for ...
Breaking Biology Technology: